Orchard Rx Ltd.

General Information


We are a commercial-stage, fully-integrated biopharmaceutical company dedicated to transforming the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Our gene therapy approach seeks to transform a patient’s own, or autologous, HSCs into a gene-modified drug product to treat the patient’s disease through a single administration. We achieve this outcome by utilizing a lentiviral vector to introduce a functional copy of a missing or faulty gene into the patient’s autologous HSCs through an ex vivo process, resulting in a drug product that can then be re-introduced into the patient at the bedside.

Employees: 100
Founded: 2015
Contact Information
Address 108 Cannon Street, London EC4N 6EU, United Kingdom
Phone Number +44 (0) 203 384 6700
Web Address http://www.orchard-tx.com
View Prospectus: Orchard Rx Ltd.
Financial Information
Market Cap $1176.7mil
Revenues $0 mil (last 12 months)
Net Income $-193.8 mil (last 12 months)
IPO Profile
Symbol ORTX
Exchange NASDAQ
Shares (millions): 14.3
Price range $14.00 - $14.00
Est. $ Volume $200.0 mil
Manager / Joint Managers J.P. Morgan/ Goldman Sachs/ Cowen
CO-Managers Wedbush PacGrow
Expected To Trade: 10/31/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change